Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,480 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Opioid Related Disorders Clear all
Completed Phase 2 Interventional

Buprenorphine Detox With Two Types of Treatment. BBD I - 10

NCT00000228
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

NCT02357901
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders
Interventions
SUBOXONE, RBP-6000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
38
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

NCT01122030
View directory record Official record
Conditions
Opioid Induced Bowel Dysfunction
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 6:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

NCT02225184
View directory record Official record
Conditions
Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence, Opiod-Related Disorders
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 26, 2026, 6:13 PM EDT
Not yet recruiting Not applicable Interventional

Remote Intervention to Prevent Overdose

NCT07128485
View directory record Official record
Conditions
Accidental Overdose of Opiate
Interventions
Overdose prevention resources, Overdose prevention education
Other · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Early Phase 1 Interventional

Cannabidiol in Opioid Use Disorder and Chronic Pain

NCT04587791
View directory record Official record
Conditions
Chronic Pain, Opioid Use Disorder
Interventions
400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol, Beta carotene oral solution without CBD
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed No phase listed Observational

Evaluating the SUBLOCADE Treatment Exit Strategy

NCT05878210
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Early Phase 1 Interventional Results available

mHealth to Help Pregnant and Postpartum Women in Recovery for Opioid Use Disorder

NCT06701123
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
uMAT-R mobile app with coaching component
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Rapid Access

NCT05528562
View directory record Official record
Conditions
Drug Use, Pre-exposure Prophylaxis (PrEP), Opioid Use Disorder
Interventions
PrEP Rapid Access, HIV self-testing, Dried blood spot testing
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 26, 2026, 6:13 PM EDT
Enrolling by invitation No phase listed Observational

Assessing Concentrations of Methadone and Its Metabolites

NCT06835582
View directory record Official record
Conditions
Opioid Use Disorder, Pain
Interventions
Methadone
Drug
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Pharmacists and Opioid Misuse

NCT03149718
View directory record Official record
Conditions
Opioid Misuse
Interventions
Brief Intervention Medication Therapy Management, Standard Medication Counseling (SMC)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Somerset, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional Results available

Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments

NCT02586896
View directory record Official record
Conditions
Opioid Dependence
Interventions
Strengths-based Case Management (SBCM), Screening, Assessment, and Referral (SAR)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Opioid Prescribing Nudge

NCT04069403
View directory record Official record
Conditions
Opioid Use, Unspecified, Prescription Drug Abuse (Not Dependent), Prescription Drug Abuse and Dependency, Health Behavior, Benzodiazepine Abuse, Benzodiazepine Dependent
Interventions
Automated Reports on prescription patterns for their patients
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 26, 2026, 6:13 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Rectal Acetaminophen Use During Oocyte Retrievals to Reduce Post-Operative Opioid Utilization

NCT03732469
View directory record Official record
Conditions
Opioid Use
Interventions
Acetaminophen, Fentanyl, Propofol
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 56 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional

Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy

NCT02243670
View directory record Official record
Conditions
Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
Interventions
AiCure monitoring and intervention
Device
Lead sponsor
AiCure
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 26, 2026, 6:13 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

NCT04759703
View directory record Official record
Conditions
Sleep Disorder, Restless Legs Syndrome, Opioid-use Disorder, Opioid Withdrawal
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Quincy, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

NCT05610072
View directory record Official record
Conditions
Cocaine Use Disorder, Opioid Use Disorder, Stimulant Use Disorder
Interventions
n-acetylcysteine, Hydromorphone, Placebo n-acetylcystine, Placebo hydromorphone
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1

NCT00218530
View directory record Official record
Conditions
Heroin Dependence
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

NCT04827992
View directory record Official record
Conditions
Opioid Use, Pain, Marijuana Use
Interventions
Cannabis, Prescription Opioid Taper Support (POTS)
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Portland, Maine • Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 26, 2026, 6:13 PM EDT
Not yet recruiting Not applicable Interventional

Helping Kentuckians Overcome Depression and Opioid Addiction With Brain Stimulation

NCT07842601
View directory record Official record
Conditions
Opioid Use Disorder, Major Depressive Disorder (MDD)
Interventions
Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 6:13 PM EDT
Recruiting Not applicable Interventional

tDCS to Decrease Opioid Relapse (UH3)

NCT06432465
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
active tDCS, sham tDCS
Device
Lead sponsor
Butler Hospital
Other
Eligibility
21 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 26, 2026, 6:13 PM EDT